Milestone Pharmaceuticals Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Milestone Pharmaceuticals Inc. (MIST) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$9.46 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-20
- Milestone Pharmaceuticals Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$9.46M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$9.46M 10-K · filed 2026-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |